NCT06949774 INcentives and ReMINDers to Improve Long-term Medication Adherence (INMIND)
| NCT ID | NCT06949774 |
| Status | Recruiting |
| Phase | — |
| Sponsor | RAND |
| Condition | HIV/AIDS |
| Study Type | INTERVENTIONAL |
| Enrollment | 550 participants |
| Start Date | 2025-04-02 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 550 participants in total. It began in 2025-04-02 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Low medication adherence when initiating antiretroviral treatment (ART) is a key barrier to HIV virologic suppression, resulting in avoidable cases of drug resistance, death, and viral transmission. Routinized pill-taking can lead to successful long-term ART adherence, and short-term behavioral economics-based supports are a novel way to overcome the limited success of existing routinization interventions. This study proposes to test this combined approach for promoting long-term ART adherence using a Stage III Sequential, Multiple Assignment, Randomized Trial (SMART) design in one of the largest HIV clinics in Uganda to identify the most cost-effective adaptive intervention that if found effective is generalizable to other settings and other chronic diseases.
Eligibility Criteria
Inclusion Criteria: * Male and female clients age 18 and older. * Started ART at Mildmay or another clinic within the preceding 2 months * Able to speak and understand either English or Luganda. * Have their own cell phone or have consistent access to someone else's phone. * Willing to receive daily text messages for the 6 months of intervention duration. * Willing and able to use the WisePill device distributed for adherence verification for the duration of the study. Exclusion Criteria: * Not mentally fit to consent. * Language other than Luganda or English. * Not willing to consistently use the Wisepill device for adherence measurement.
Contact & Investigator
Sebastian Linnemayr, Ph.D
PRINCIPAL INVESTIGATOR
RAND
Frequently Asked Questions
Who can join the NCT06949774 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying HIV/AIDS. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06949774 currently recruiting?
Yes, NCT06949774 is actively recruiting participants. Contact the research team at yvonne.karamagi@mildmay.or.ug for enrollment information.
Where is the NCT06949774 trial being conducted?
This trial is being conducted at Kampala, Uganda.
Who is sponsoring the NCT06949774 clinical trial?
NCT06949774 is sponsored by RAND. The principal investigator is Sebastian Linnemayr, Ph.D at RAND. The trial plans to enroll 550 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.